This study is particularly relevant to anyone diagnosed with TNBC.
Panel testing is currently available and can be used in clinical practice.
More research needs to be done to determine the lifetime risk of TNBC for the genes tested in this study.
Strength of Science: Medium-High
This is a well-designed study of TNBC patients. Panel testing was used to identify inherited mutations in about 20 genes in 11,000 TNBC patients.
One limitation of this study was the data used for controls. Controls were not matched to study participants. As a substitute, mutation frequencies for the genes studied came from large publically available data bases. While not ideal, these data have successfully been used in similar studies.
Research Timeline: Post Approval
Guidelines already recommend genetic counseling and testing for anyone diagnosed with triple-negative breast cancer age 60 or younger.
More research will need to be done to refine the actual risk of TNBC for people who test positive for a mutation in each of the genes.